Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: JACC Heart Fail. 2022 Mar 9;10(4):227–234. doi: 10.1016/j.jchf.2021.12.006

Table 2.

Hazard ratios (95% confidence interval) for initial and recurrent heart failure hospitalization according to randomized groups and type 2 diabetes (T2D) status*

Sequence of heart
failure
hospitalization		 Prevalent T2D at baseline
 No prevalent T2D at baseline
 P interaction T2D x
omega-3 fatty acids
Active
Omega-3
Events/Total		 Omega-3
placebo
Events/Tota1		 Hazard Ratio
(95% CI)
p-value		 Active
Omega-3
Events/Total		 Omega-3
placebo
Events/Tota1		 Hazard Ratio
(95% CI)
p-value
Initial 65/1,784 90/1,738 0.69 (0.50-0.95) 177/11,053 164/11,163 1.09 (0.88-1.34) 0.019
Recurrent ƚ 88/1,879 158/1,904 0.53 (0.41-0.69) 240/11,357 226/11,395 1.07 (0.89-1.28) <0.0001
*

All models adjusted for age, sex, and vitamin D assignment versus placebo

ƚ

Hnclusive of 36 participants with prevalent heart failure at randomization